معرفی
Chien-Shing Chen, MD, PhD is a Professor in both the Department of Medicine and Biochemistry Division within the School of Medicine at Loma Linda University. With over three decades of academic service since 1993, he maintains active research programs in molecular oncology and hematological malignancies.
Education:
- Doctor of Philosophy, University of Minnesota Twin Cities (1992)
- Doctor of Medicine, China Medical University (1985)
- Diploma - Professional, University of Washington Seattle (1998)
Dr. Chen's research focuses on the molecular mechanisms of acute myeloid leukemia (AML), particularly FLT3-mutated cases, drug resistance pathways, and novel therapeutic approaches including vitamin D-based interventions. His work bridges basic science discoveries with translational applications, investigating cancer stem cells, metabolic reprogramming in leukemia, and the tumor microenvironment. Key contributions include elucidating NFκB2 signaling pathways, vitamin D's role in leukemia differentiation, and mechanisms of TKI resistance.
Analysis of his 114 publications (1993-2025) reveals consistent focus on AML pathogenesis and treatment resistance, with recent work emphasizing immunometabolism, NFκB2-coordinated genome regulation, and nutrient-based immunotherapies. His research demonstrates strong interdisciplinary collaboration across hematology, molecular biology, and immunology.
Collaborations and Research Impact: Dr. Chen maintains extensive collaborations with investigators including H. Cao, Y. Xu, D.J. Baylink, and M.E. Reeves. His laboratory has contributed significantly to understanding CD44+ cancer stem cells in AML, vitamin D metabolism in leukemia, and novel therapeutic targets for drug-resistant disease. Current work explores competitive nutrient-based T-cell immunotherapies and dual mitochondrial/nuclear genome targeting strategies.
